Travel Medicine and Infectious Disease
Volume 9, Issue 3 , Pages 126-134 , May 2011

Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine

  • Uzma N. Sarwar
    • ,
  • Sandra Sitar
    • ,
  • Julie E. Ledgerwood

      Affiliations

    • Corresponding Author InformationCorresponding author at: Vaccine Research Center, NIAID, NIH, 9000 Rockville Pike, Bldg 10, CRC, Room 5-2440, Bethesda, MD 20892, USA. Tel.: +1 301 594 8502; fax: +1 301 451 4651.

Received 11 May 2010 ,Accepted 17 May 2010.

References 

  1. Bray M. Epidemiology, pathogenesis and clinical manifestations of Ebola and Marburg hemorrhagic fever. Uptodate 2009 July 28.
  2. Murdoc D. Diseases potentially acquired by travel to Sub Saharan Africa. Uptodate 2008 September 8.
  3. Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis. 2007;196(Suppl. 2):S438–S443
  4. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis. 2001;33:1707–1712
  5. Ebola hemorrhagic fever: known cases and outbreaks of ebola hemorrhagic fever in chronological order. CDC; 2009 August 26;
  6. Special pathogens branch. Outbreak postings. CDC; 2009 December 23;
  7. Bermejo M, Rodriguez-Teijeiro JD, Illera G, Barroso A, Vila C, Walsh PD. Ebola outbreak killed 5000 gorillas. Science. 2006;314:1564
  8. Thacker PD. An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power. JAMA. 2003;290:317–319
  9. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438:575–576
  10. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 2009;5:e1000536
  11. CDC. Imported case of Marburg hemorrhagic fever-Colorado 2008. MMWR - morbidity & mortality weekly report; 2009 December 18. p. 1377–81.
  12. Stroher U, Feldmann H. Progress towards the treatment of ebola haemorrhagic fever. Expert Opin Investig Drugs. 2006;15:1523–1535
  13. Marburg hemorrhagic fever. WHO; 2008, July;
  14. Bray M. Defense against filoviruses used as biological weapons. Antivir Res. 2003;57:53–60
  15. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179(Suppl. 1):S87–S91
  16. Fisher-Hoch SP. Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bull. 2005;73-74:123–137
  17. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210–2215
  18. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?. Apoptosis. 2000;5:5–7
  19. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5:423–426
  20. Schnittler HJ, Feldmann H. Viral hemorrhagic fever–a vascular disease?. Thromb Haemost. 2003;89:967–972
  21. Saijo M, Niikura M, Ikegami T, Kurane I, Kurata T, Morikawa S. Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins. Clin Vaccine Immunol. 2006;13:444–451
  22. Bray M. Diagnosis and treatment of Ebola and Marburg hemorrhagic fever. Uptodate 2008 September 30.
  23. Bray M, Paragas J. Experimental therapy of filovirus infections. Antivir Res. 2002;54:1–17
  24. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis. 1999;179:S18–S23
  25. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis. 1999;179(Suppl. 1):S224–S234
  26. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Young HA, Formenty P, Fritz EA. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis. 2007;196(Suppl. 2):S372–S381
  27. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953–1958
  28. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T. Recombinant human activated protein C for the post exposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196(Suppl. 2):S390–S399
  29. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA. Post exposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006;367:1399–1404
  30. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F. Recombinant vesicular stomatitis virus vector mediates post exposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008;82:5664–5668
  31. Slenczka W, Klenk HD. Forty years of marburg virus. J Infect Dis. 2007;196(Suppl. 2):S131–S135
  32. Balter M. Emerging diseases. On the trail of Ebola and Marburg viruses. Science. 2000;290:923–925
  33. Borchert M, Boelaert M, Sleurs H, Muyembe-Tamfum JJ, Pirard P, Colebunders R. Viewpoint: filovirus haemorrhagic fever outbreaks: much ado about nothing?. Trop Med Int Health. 2000;5:318–324
  34. Peters CJ. Marburg and Ebola–arming ourselves against the deadly filoviruses. N Engl J Med. 2005;352:2571–2573
  35. Pourrut X, Kumulungui B, Wittmann T, Moussavou G, Delicat A, Yaba P. The natural history of Ebola virus in Africa. Microbes Infect. 2005;7:1005–1014
  36. Known cases and outbreaks of marburg hemorrhagic fever, in chronological order. CDC; 2009, July 31st;
  37. Bausch DG, Borchert M, Grein T, Roth C, Swanepoel R, Libande ML. Risk factors for marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis. 2003;9:1531–1537
  38. Dutch tourist infected with Marburg Virus. Environment NIfPHat; 2008 July 10;
  39. Timen A, Koopmans MP, Vossen AC, van Doornum GJ, Gunther S, van den Berkmortel F. Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis. 2009;15:1171–1175
  40. Case of Marburg hemorrhagic fever imported into the Netherlands from Uganda. WHO; 2008 July 10;
  41. Barnes M, Fuijita NK. Marburg virus in a Wheat Ridge Colorado hospital 2008. Bethesda: Maryland National Institutes of Health; 2009, June 22;
  42. Clinician outreach and communication activity update for February 2009. CDC; 2009 February;
  43. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005;23:3033–3042
  44. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine. 2004;22:3495–3502
  45. Bausch DG, Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert Rev Vaccines. 2007;6:57–74
  46. Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines. 2003;2:777–789
  47. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8:503–507
  48. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–1277
  49. Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol. 2003;77:9733–9737
  50. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM. Chimeric human parainfluenza virus bearing the ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against ebola virus challenge. Virology. 2009;383:348–361
  51. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83:7296–7304
  52. Geisbert T, Daddario KM, Lewis MG, Geisbert J, Grolla A, Leung A. Vesicular stomatitis virus-based ebola vaccine is well tolerated and protects immunocompromised nonhuman primates. PLoS Med. 2008;4:
  53. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–609
  54. Graham B. Safety and immunogenicity of a multiclade HIV-1 recombinant adenovirus vacine boost in prior recipients of a multiclade HIV-1 DNA vaccine (paper #15(827P)) AIDS Vaccine 2005. Montreal: Canada; 2005;
  55. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424:681–684
  56. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, Holman DH. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol. 2008;15:460–467
  57. Ledgerwood JE, Costner, P, Desai, N, Holman, L, Enama, ME, Yamshchikov, et al. A replication defective recombinant Ad5 vaccine expressing ebola GP is safe and immunogenic in healthy Adults, submitted for publication.

PII: S1477-8939(10)00068-2

doi: 10.1016/j.tmaid.2010.05.003

Travel Medicine and Infectious Disease
Volume 9, Issue 3 , Pages 126-134 , May 2011

Article Tools

* Image Usage & Resolution